W. Landgraf

发表

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes

M. Hanefeld, T. Forst, F. Schaper, 2013, Acta Diabetologica.

The emergence of biosimilar insulin preparations--a cause for concern?

D. Owens, R. Bretzel, M. Kuhlmann, 2012, Diabetes technology & therapeutics.

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat‐to‐target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

D. Owens, A. Kautzky-Willer, B. Charbonnel, 2017, Diabetes, obesity & metabolism.

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy

J. Sandow, W. Landgraf, 2016, European endocrinology.

Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus.

M. Hanefeld, S. Bornstein, S. Bilz, 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin‐naive individuals with type 2 diabetes mellitus

D. Owens, B. Frier, G. Bolli, 2018, Diabetes, obesity & metabolism.

Evaluation of the JuniorSTAR® Half-unit Insulin Pen in Young People with Type 1 Diabetes - User Perspectives.

D. Klonoff, T. Danne, I. Rabbone, 2013, European endocrinology.

Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: post hoc cluster assignment analysis of over 12,000 study participants.

L. Groop, D. Owens, B. Frier, 2022, Diabetes research and clinical practice.

ACE inhibition and atherogenesis 1,2

B. Schölkens, W. Landgraf, 2002 .

ACE inhibition and atherogenesis.

B. Schölkens, W. Landgraf, 2002, Canadian journal of physiology and pharmacology.

[ACE inhibition and atherogenesis].

B. Schölkens, W. Landgraf, 2001, Der Internist.

Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.

B. Sethi, P. Aschner, F. Gómez-Peralta, 2015, Journal of diabetes and its complications.

Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

R. Becker, J. Sandow, W. Landgraf, 2015, European endocrinology.

Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy

D. Owens, J. Mbanya, J. Sandow, 2017, European endocrinology.

Basal insulin glargine vs prandial insulin lispro in type 2 diabetes – Authors' reply

R. Bretzel, T. Linn, W. Landgraf, 2008, The Lancet.

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C‐peptide levels in insulin‐naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

P. Home, G. Bolli, W. Landgraf, 2020, Diabetes, obesity & metabolism.

Fasting C‐peptide, a biomarker for hypoglycaemia risk in insulin‐naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL

D. Owens, B. Frier, G. Bolli, 2019, Diabetes, obesity & metabolism.

Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials.

J. Chan, S. Tsai, S. Chan, 2018, Diabetes research and clinical practice.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

C. Mathieu, M. Riddle, G. Bolli, 2014, Diabetes, obesity & metabolism.

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

D. Owens, B. Frier, P. Home, 2019, Diabetes, obesity & metabolism.

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

M. Hanefeld, W. Landgraf, Ling Gao, 2017, Cardiovascular Diabetology.

Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

T. Kohlmann, S. Jacob, B. Kulzer, 2015, Health and Quality of Life Outcomes.

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

D. Owens, W. Landgraf, M. Dain, 2014, Diabetes research and clinical practice.

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.

D. Owens, P. Mullins, W. Landgraf, 2017, Diabetes research and clinical practice.

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance

W. Landgraf, Stephen L Lin, Z. Doder, 2015, European endocrinology.

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

D. Owens, R. Bretzel, T. Linn, 2008, The Lancet.

Incidence of Hypoglycaemia in Patients with Type 2 Diabetes - A Subgroup Analysis from the GINGER study.

A. Fritsche, H. Häring, W. Landgraf, 2013, European endocrinology.

Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials.

D. Owens, B. Frier, G. Bolli, 2023, Primary care diabetes.

A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

R. Bergenstal, J. DeVries, A. Barnett, 2014, European endocrinology.

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents

D. Owens, R. Bretzel, T. Linn, 2009, Diabetes Care.

Comparative efficacy and safety of Gla‐300 versus IDegAsp in insulin‐naïve people with type 2 diabetes mellitus uncontrolled on oral anti‐diabetics

L. Zeng, M. A. Mabunay, P. Guyot, 2023, Diabetes, obesity & metabolism.

D. Owens, W. Landgraf, M. Dain, 2014, Diabetes research and clinical practice.

Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis

G. Bolli, W. Landgraf, B. M. Frier, 2024, Diabetes therapy : research, treatment and education of diabetes and related disorders.

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

B. Frier, G. Bolli, W. Landgraf, 2023, Diabetes, obesity & metabolism.